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Abstract 
Background: The role of common bile duct (CBD) stenting in the establishment of bile stream in the elderly patients 
and the ones who are not good candidates for surgery due to not responding to treatments was well documented in 
previous studies. The current study aimed at investigating the effect of adding Ursodeoxycholic acid (UDCA) to CBD 
stenting alone in order to reduce the size of large and multiple CBD stones.
Methods: Clinical outcomes including success rates in CBD stones clearance, incidence of pancreatitis, perfora-
tion, bleeding, as well as, decrease in size of stones and liver enzymes after a two-month period were assessed in the 
UDCA + CBD stenting group.
Results: A total of 64 patients referring to Shahid Beheshti Hospital in Qom, Iran with multiple or large CBD stones 
(above three or larger than 15 mm) received standard endoscopic therapies and UDCA + CBD stenting (group B) 
and controls only received standard endoscopic therapies with only CBD stenting (group A). The mean reduction in 
the size of stones in group B was significantly higher than that of group A (3.22 ± 1.31 vs 4.09 ± 1.87 mm) (p = 0.034). 
There was no difference in the incidence rate of complications including pancreatitis, cholangitis, bleeding, and perfo-
ration between the two groups (P > 0.05).
Conclusion: Adding UDCA to CBD stenting, due to decrease in the stone size and subsequently facilitation of the 
stones outlet, can be considered as the first-line treatment for patients with large and multiple CBD stones. Also, in 
the cases with large or multi stones may be effective in reducing size and subsequently stone retrieval.
Trial registry The study protocol was approved by the Ethics Committee of Qom University of Medical Sciences 
(ethical code: IR.MUQ.REC.1397.075); the study was also registered in the Iranian Registry of Clinical Trials (No. 
IRCT20161205031252N8). This study adheres to CONSORT guidelines.
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Background
Common bile duct (CBD) stone is found in approxi-
mately 7–12% of patients undergoing cholecys-
tectomy for symptomatic gallstones, and is a 
common indication for endoscopic retrograde 
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choangiopancreatography (ERCP). The CBD stones 
vary in size, from 1–2  mm to above 3  cm in diame-
ter. ERCP with endoscopic sphincterotomy and stone 
retrieval with basket and balloon is the therapeutic 
options commonly used to treat CBD stones. It is esti-
mated that roughly 85–95% of all CBD stones can be 
effectively treated with these common methods [1].
CBD stones with a maximum diameter of 1.5  cm 
can be removed with the endoscopic sphincterotomy 
technique. By increasing the size of stone, the success 
rate of these methods and the risk of complications 
such as perforation, cholangitis, and pancreatitis are 
increased; therefore, the utilization of methods with 
maximum success rates and minimum complications 
seems essential. Stones ≥ 15 mm should be broken up 
before extraction [2–4].
To treat stones called complicated stones, sev-
eral methods including various lithotripsy tech-
niques (electrohydraulic lithotripsy (EHL) and laser 
lithotripsy (LL), endoscopic papillary balloon dilata-
tion (EPBD), sphincterotomy, and CBD stenting are 
applied. According to the results of different studies, 
EHL is associated with increased risk of duct rupture 
and EPBD with increased risk of pancreatitis. In older 
patients with concomitant critical illnesses that sur-
gical procedures or other endoscopic measures may 
threaten their lives, the use of less invasive methods 
with minimal complications seems logic [5, 6].
Hydrophilic bile acids, such as ursodeoxycholic acid 
(UDCA), are used to treat CBD stones, especially cho-
lesterol containing stones. Although the treatment of 
choice for cholelithiasis is cholecystectomy, patients 
with small cholesterol stones, without severe symp-
toms, and proper function of the gallbladder receive 
UDCA therapy, if they are not good candidates for sur-
gery. Studies indicate that up to 60% of patients have 
a chance to completely recover from CBD stones with 
pharmacotherapies if they are good candidates for 
medical treatment [7, 8].
Regarding the high risk of complications in patients 
with large and multiple CBD stones, it is reasonable to 
adopt therapeutic methods with maximum efficacy in 
order to reduce the size of the stones. Several studies 
indicated the efficacy of CBD stenting following the 
endoscopic treatment to reduce the size of large CBD 
stones. The current study aimed at investigating the 
effect of adding UDCA accompanied by CBD stenting 
in order to reduce the size of stones and increase the 
success rate of endoscopic treatment in patients with 
large and multiple CBD stones [9].
Methods
This randomized, controlled, clinical trial study was 
conducted on patients with multiple (≥ 3) and/or large 
(> 15 mm in diameter) CBD stones. The statistical sample 
was comprised of patients with large and multiple CBD 
stones that were candidates for endoscopic treatment by 
ERCP. The inclusion criteria were both ≥ 3 CBD stones 
and with ≥ 15  mm in diameter. The exclusion criteria 
were history of stomach, duodenum, or CBD surgery, 
having gastrointestinal stenosis, hemorrhagic disorders, 
high-risk cardiovascular diseases, and unwillingness to 
participate in the study.
The sample size required for the current study was 
determined 32 in each group using the sample size for-
mula, based on the type 1 error as 0.05 and the type 2 
error as 0.20.
The eligible patients after signing the informed consent 
form were randomly assigned to each of the therapeu-
tic group A or B using the permuted block randomiza-
tion method. Group A (control) underwent endoscopic 
therapy with ERCP and stent insertion, and the group 
B (intervention) received UDCA therapy in addition to 
ERCP and stenting, for two months. Treatments were 
appointed to groups A and B by coin tossing. In the cur-
rent study, 10-Fr plastic stents, 8–14  cm length, were 
used for the subjects based on their CBD length. UDCA 
tablets 300 mg (Tehran Pharm Company) were adminis-
tered to the subjects three times daily per os.
The information of patients in both groups were 
recorded in a checklist including demographic character-
istics such as age, gender, height, and weight, history of 
underlying diseases, history of pancreatitis, and the size 
and number of CBD stones (measured before ERCP). 
The liver transaminases, alkaline phosphatase, and serum 
bilirubin levels were measured before the procedure and 
recorded in the patient’s checklist. Patients then under-
went ERCP. ERCPs were conducted by three expert gas-
troenterologists. The number and size of the stones were 
recorded by fluoroscopy during the ERCP, after the injec-
tion of contrast material and radiography. The CBD stent 
was then inserted. Information on complications dur-
ing the procedure including perforation of the CBD and 
bleeding was recorded in the patient’s checklist.
Patients in group B were treated with UDCA and both 
groups underwent ERCP again after two months in order 
to remove the stent. In the second turn of the ERCP, 
complications were monitored during the procedure 
and after 24  h. The success rate, defined as a reduction 
in the number and/or size of CBD stones, was evalu-
ated through ERCP and the results were recorded in the 
checklist.
Data were analyzed with SPSS 18 software using chi-
square, independent and paired samples t-test, and 
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analysis of covariance (ANCOVA). Mean and stand-
ard deviation were used to express the data. The 
P-value < 0.05 was considered as the level of significance.
Results
Out of 64 patients enrolled in the current clinical trial, 
thirty-two cases in the control group underwent CBD 
stenting alone (group A) and the other 32 cases in the 
intervention group underwent CBD stenting + UDCA 
(group B). There were 16 females in each group and there 
was no difference in gender distribution between the 
groups. The mean age of patients in groups A and B was 
44.31 ± 12.55 and 41.33 ± 41.3  years, respectively. The 
demographic variables including age and BMI were not 
significantly different between the two groups. Before 
ERCP, the average number of stones in groups A and B 
were 3.34 ± 2.06 and 3.56 ± 2.26 respectively, that were 
similar in the two groups (P = 0.67). The findings are 
shown in Table 1. The indication for ERCP in all patients 
was biliary obstruction due to stone and no evidence of 
malignancy was detected in cases. Mean levels of liver 
transaminases, bilirubin, and alkaline phosphatase sum-
marized in Table  2 showed no significant differences 
between the two groups.
CBD cannulation was successfully performed in 86% of 
the patients and the success rate in the two groups had 
no difference (P = 0.154). The rate of complications dur-
ing and after ERCP, including pancreatitis, cholangitis, 
and bleeding, summarized in Table 1, showed no signifi-
cant differences between the two groups. ERCP-related 
perforation was not observed in any of the groups.
The average size of stones after two months in groups A 
and B were 3.22 ± 1.31 and 4.09 ± 1.87 mm, respectively 
that were significantly higher in group B (P = 0.034). The 
success rate of CBD stones clearance was 27 (84.4%) in 
group A and 30 (93.8%) in group B. There was no sig-
nificant difference between two groups in terms of stone 
clearance rate (P = 0.230).
Discussion
CBD stones vary in size, and most of them are treated 
with standard procedures. However, in less than 50% of 
cases, endoscopic sphincterotomy is difficult because of 
abnormal anatomy of the duct, abnormal stone location, 
large size, and high number of stones are effective in this 
condition [1, 2, 10–13]. Several methods are proposed 
for the treatment of large stones of which endoscopic 
CBD stenting is considered as an effective alternative [1, 
5]. Reduction in the size and number of CBD stones is 
reported after two months of inserting the stent with a 
high success rate [1, 5, 9].
A number of studies showed the efficacy of pharmaco-
therapy in the treatment of CBD stones with hydrophilic 
bile acids, especially UDCA. It is also used in the treat-
ment of chronic cholestatic diseases, such as primary 
Table 1 Findings and  complications in  both  groups 
underwent to  only  CBD stenting (group A) 
and UDCA + CBD stenting (group B)










Pancreatitis No 29 (90.6) 27 (87.1) 0.880
Mild 2 (6.2) 3 (9.7)
Moderate 1 (3.1) 1 (3.1)
Severe 0 0
Cholangitis No 31 (96.9) 31 (96.9) 1
Yes 1 (3.1) 1 (3.1)
Perforation No 32 (100) 32 (100) 1
Yes 0 0
Sphincterotomy No 32 (100) 32 (100) 1
Yes 0 0
Stone removal Yes 27 (84.4) 30 (93.8) 0.230
No 5 (15.6) 2 (6.2)
Diverticula Yes 28 (87.5) 26 (81.2) 0.491
No 4 (12.5) 6 (18.8)
PD stent Yes 2 (6.2) 3 (9.4) 0.641
No 30 (93.8) 29 (90.6)
PD Cannulation Yes 25 (78.1) 30 (93.8) 0.154
No 5 (15.6) 2. (6.2)
GIB Yes 5 (16.6) 3 (9.4) 0.450
No 27 (84.4) 29 (90.6)
Table 2 Comparison of liver tests and reduction in the size 
and  number of  stone between  two groups underwent 
to  only  CBD stenting (group A) and  UDCA + CBD stenting 
(group B)
ALT Alanine aminotransferase; AST Aspartate aminotransferase
*Based on Independent T-test
# Reference range for ALT, AST, total Bilirubin and direct bilirubin are 13–40 U/L, 






Stone size in mm
Mean (SD)
3.22 ± 1.31 4.09 ± 1.87 0.034
Number of stones
Mean (SD)






SGPT (ALT), U/L 184.38 ± 134.44 196.34 ± 114.5 0.754
SGOT (AST), U/L 141.31 ± 99.72 153.97 ± 114.5 0.639
Total Bilirubin, mg/dL 5.78 ± 1.64 5.47 ± 1.98 0.495
Direct Bilirubin, mg/dL 4.13 ± 1.18 4.06 ± 1.64 0.862
Amylase Serum, U/L 120.8 ± 172.29 127.19 ± 167.3 0.881
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biliary cirrhosis (PBC), as a useful and effective therapeu-
tic option to protect the liver and slowdown the progres-
sion of liver damage. UDCA inhibits biliary cholesterol 
secretion, decreases intestinal absorption of cholesterol, 
increases hepatocyte bile secretion, and improves the 
evacuation of gallbladder of bile and other constituents. It 
also improves the contraction of gallbladder muscle and 
reduces inflammation in its wall. However, gallstones are 
treated medically with UDCA in cases with the mild clin-
ical symptoms, stones smaller than 5–10 mm in diameter, 
and appropriate function of the gallbladder. The presence 
of calcium salts in the gallstones, observed as calcifica-
tion in CT images, reduces the efficacy of UCDA therapy 
[14–17]. However, clinical studies show that if good can-
didates for medical treatment are selected, up to 60% are 
completely cleared of CBD stones after 12–24 months of 
treatment [7, 8].
The current study aimed at examining the efficacy of 
the combination of two methods of stenting and UDCA 
therapy in reducing the size of large and number of mul-
tiple CBD stones. The results showed that the utilized 
method could reduce the size of stones by 4 mm in aver-
age that was significantly higher than that of the control 
group. Also, the number of CBD stones removed from 
CBD in the intervention group was higher than the con-
trol group (93.8% vs. 84.4%); however, the difference was 
statistically insignificant (Table 1).
Pancreatitis is one of the most important diseases that 
predispose ERCP to complications. The overall inci-
dence of pancreatitis was 11% in the present study, with 
three cases in the control group and four in the inter-
vention group. There was no significant difference in the 
incidence of pancreatitis between the two groups. Pan-
creatitis is identified as the most common post-ERCP 
complication, and its prevalence generally varies from 3 
to 5% in studies, but also can vary from 1 to 16% depend-
ing on selected patients [14–16]. In the present study, 
considering the patients conditions with large and mul-
tiple stones, procedures were generally more risky and 
the high rate of pancreatitis was expected in comparison 
with the total reported rate.
Cholangitis was observed in two patients (3.13%), of 
which one was in the control group and the other in the 
intervention group. The incidence rate of cholangitis 
was also different in studies; it was 3.8% in the study by 
Hong [17] that was similar to that of the current study, 
but in the study by Horiuchi [18] it was 13%; the different 
results can be attributed to patients’ differences in vari-
ous studies.
In the recent study, the success rate in complete clear-
ance of CBD stones was 93.8% in the intervention group 
and 84.4% in the control group. The results was consist-
ent with those of previous studies, including Horiuchi 
(93%) [18], Hong (94%) [17], Hui (94.7%) [19], Fan (95.6%) 
[4] and Ye (94.1%) [6].
Compared to our previous studies, the additional 
effects of this study is associated to this fact that the pre-
scribing UDCA along with CBD stenting leads to a fur-
ther reduction in the size of the stones without increasing 
complications [9, 20]. However, according to the find-
ings, there was no significant difference in CBD stones 
clearance rate. It should be noted that as a rule, UDCA 
is used in long-term treatments (at least 12–24 months), 
and such circumstances lead to a significant reduction 
in the size of the stones, especially cholesterol stones. 
The main limitation of this study is related to the dura-
tion of pharmacotherapy in the current study which was 
much shorter than its routine duration (2  months vs. 
12 months). Also, there was also no screening for stones 
in terms of the type and presence of calcification, espe-
cially peripheral calcifications. Given to the fact that 
UDCA is less effective in cases of calcified stones and 
patients characteristics is very important in response 
to UDCA therapy, subsequent clinical trials with larger 
populations and a more precise selection of patients can 
be useful in obtaining more conclusive results about the 
efficacy of the utilized method in the clearance of difficult 
CBD stones.
Conclusion
Generally, it can be concluded that while common bile 
duct (CBD) stenting is an effective method for retain-
ing the continuity of the bile flow in the elderly patients 
and the ones who are not good candidates for surgical 
treatment, adding UDCA to this treatment can improve 
the outcomes. Also, in patients with large and multiple 
stones, procedures were generally accompanied with 
more risk and may lead to higher rate of pancreatitis. 
Results of the current study demonstrated that combina-
tion of ERCP and CBD stenting with medical treatment 
with UDCA, is more effective in reducing of the size of 
CBD stones than CBD stenting alone. Also, we achieved 
to high success rate in complete clearance of CBD stones. 
Beside of these benefits we also do not find any signifi-
cant differences in the incidence of pancreatitis between 
the two groups. Therefore, we conclude that this new 
combination method provided us further reduction in 
the size of the stones in patients with large and multiple 
biliary stones without increasing complications that were 
not reported previously.
Abbreviations
CBD: Common bile duct; UDCA: Ursodeoxycholic acid; ERCP: Endoscopic 
retrograde choangiopancreatography; EHL: Electrohydraulic lithotripsy; LL: 
Laser lithotripsy; EPBD: Endoscopic papillary balloon dilatation; PBC: Primary 
biliary cirrhosis.
Page 5 of 5Hormati et al. BMC Gastroenterol          (2020) 20:374  
•
 
fast, convenient online submission
 •
  
thorough peer review by experienced researchers in your field
• 
 
rapid publication on acceptance
• 
 
support for research data, including large and complex data types
•
  
gold Open Access which fosters wider collaboration and increased citations 
 
maximum visibility for your research: over 100M website views per year •
  At BMC, research is always in progress.
Learn more biomedcentral.com/submissions
Ready to submit your research ?  Choose BMC and benefit from: 
Acknowledgements
The authors thank A Jabari, from the Qom University of Medical Sciences, 
Qom, Iran, for the editing assistance.
Authors’ contributions
AH, MG and SS, writing and original draft preparation. FA, correspondence(s). 
MM, AM and GS designing, investigation and writing. SA, Review and revise of 
the manuscript. All authors have read and approved the manuscript.
Funding
This work was not supported financially by any institution.
Availability of data and materials
All data and materials are available from the corresponding author.
Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of Qom 
University of Medical Sciences (ethical code: IR.MUQ.REC.1397.075); the 
study was also registered in the Iranian Registry of Clinical Trials (No. 





The authors declare that they have no competing interests.
Author details
1 Gastroenterology and Hepatology Diseases Research Center, Qom University 
of Medical Sciences, Qom, Iran. 2 Gastrointestinal and Liver Diseases Research 
Center, Iran University of Medical Sciences, Tehran, Iran. 3 Research Center 
for Environmental Pollutants, Qom University of Medical Sciences, Qom, Iran. 
4 Department of Internal Medicine, Gatroenterohepatology Research Center, 
Shiraz University of Medical Sciences, Shiraz, Iran. 
Received: 1 September 2020   Accepted: 2 November 2020
References
 1. Freitas ML, Bell RL, Duffy AJ. Choledocholithiasis: evolving standards for 
diagnosis and management. World J Gastroenterol. 2006;12(20):3162–7.
 2. Disario JA, Freeman ML, Bjorkman DJ, Macmathuna P, Petersen BT, Jaffe 
PE, et al. Endoscopic balloon dilation compared with sphincterotomy for 
extraction of bile duct stones. Gastroenterology. 2004;127(5):1291–9.
 3. Aslan F, Arabul M, Celik M, Alper E, Unsal B. The effect of biliary 
stenting on difficult common bile duct stones. Prz Gastroenterol. 
2014;9(2):109–15.
 4. Fan Z, Hawes R, Lawrence C, Zhang X, Zhang X, Lv W. Analysis of plastic 
stents in the treatment of large common bile duct stones in 45 patients. 
Dig Endosc. 2011;23(1):86–90.
 5. Yang J, Peng JY, Chen W. Endoscopic biliary stenting for irretrievable 
common bile duct stones: Indications, advantages, disadvantages, and 
follow-up results. Surgeon. 2012;10(4):211–7.
 6. Ye X, Huai J, Sun X. Effectiveness and safety of biliary stenting in the man-
agement of difficult common bile duct stones in elderly patients. Turk J 
Gastroenterol. 2016;27(1):30–6.
 7. Tangedahl T, Carey WD, Ferguson DR, Forsythe S, Williams M, Paradis 
K, et al. Drug and treatment efficacy of chenodeoxycholic acid in 97 
patients with cholelithiasis and increased surgical risk. Dig Dis Sci. 
1983;28(6):545–51.
 8. Maton PN, Iser JH, Reuben A, Saxton HM, Murphy GM, Dowling RH. 
Outcome of chenodeoxycholic acid (CDCA) treatment in 125 patients 
with radiolucent gallstones. Factors influencing efficacy, withdrawal, 
symptoms and side effects and post-dissolution recurrence. Medicine 
(Baltimore). 1982;61(2):86–97.
 9. Hormati A, Ghadir M, Sarkeshikian SS, Pezeshki Modarres M, Rafiei 
M, Alemi F. Efficacy of Common Bile Duct Stenting for Large Stones. 
2017;22(3):5.
 10. Samardzic J, Latic F, Kraljik D, Pitlovic V, Mrkovic H, Miskic D, et al. Treat-
ment of common bile duct stones–is the role of ERCP changed in era of 
minimally invasive surgery? Med Arh. 2010;64(3):187–8.
 11. Stromberg C, Nilsson M. Nationwide study of the treatment of com-
mon bile duct stones in Sweden between 1965 and 2009. Br J Surg. 
2011;98(12):1766–74.
 12. Binmoeller KF, Bruckner M, Thonke F, Soehendra N. Treatment of difficult 
bile duct stones using mechanical, electrohydraulic and extracorporeal 
shock wave lithotripsy. Endoscopy. 1993;25(3):201–6.
 13. Lauri A, Horton RC, Davidson BR, Burroughs AK, Dooley JS. Endoscopic 
extraction of bile duct stones: management related to stone size. Gut. 
1993;34(12):1718–21.
 14. Cheon YK, Cho KB, Watkins JL, McHenry L, Fogel EL, Sherman S, et al. Fre-
quency and severity of post-ERCP pancreatitis correlated with extent of 
pancreatic ductal opacification. Gastrointest Endosc. 2007;65(3):385–93.
 15. Cotton PB, Garrow DA, Gallagher J, Romagnuolo J. Risk factors for com-
plications after ERCP: a multivariate analysis of 11,497 procedures over 12 
years. Gastrointest Endosc. 2009;70(1):80–8.
 16. Barthet M, Lesavre N, Desjeux A, Gasmi M, Berthezene P, Berdah S, et al. 
Complications of endoscopic sphincterotomy: results from a single 
tertiary referral center. Endoscopy. 2002;34(12):991–7.
 17. Hong WD, Zhu QH, Huang QK. Endoscopic sphincterotomy plus 
endoprostheses in the treatment of large or multiple common bile duct 
stones. Dig Endosc. 2011;23(3):240–3.
 18. Horiuchi A, Nakayama Y, Kajiyama M, Kato N, Kamijima T, Graham DY, et al. 
Biliary stenting in the management of large or multiple common bile 
duct stones. Gastrointest Endosc. 2010;71(7):1200-3.e2.
 19. Hui CK, Lai KC, Ng M, Wong WM, Yuen MF, Lam SK, et al. Retained 
common bile duct stones: a comparison between biliary stenting and 
complete clearance of stones by electrohydraulic lithotripsy. Aliment 
Pharmacol Ther. 2003;17(2):289–96.
 20. Honarkar Z, Alemi F, Hormati A. Severe Post-ERCP Pancreatitis Following 
Pancreatic Duct Stenting for Needle Knife Common Bile Duct Cannula-
tion: a Case Series and Review of Literature. 2020;25(2):6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub-
lished maps and institutional affiliations.
